We were incorporated in the State of Nevada on November 16, 2009 under the
name “Online Disruptive Technologies, Inc.” with authorized capital
of 500,000,000 shares of common stock with a par value of $0.001 per share and
20,000,000 shares of preferred stock with a par value of $0.001 per share. On
March 24, 2010, we entered into a share purchase agreement with Benjamin Cherniak,
whereby we acquired all of the issued and outstanding shares of RelationshipScoreboard.com
Entertainment, Inc. (“RSE”) in consideration for the issuance of
16,000,000 of our common shares. RSE was incorporated in the State of Nevada
on November 16, 2009. There were no related party interests in the acquisition
of RSE.
The Savicell™ platform is a blood test designed for the early detection
of disease. It is a broad platform with applications for cancer, autoimmune
diseases, and infectious diseases. While our focus initially is on early diagnosis
of disease, we believe our technology may have additional applications in drug
response monitoring for therapies that impact immune response. Immunotherapy,
both for treating cancer and autoimmune diseases, is an example where metabolic
shift profiles could indicate response to drug treatment.
Initially, Savicell is focused on the multibillion-dollar cancer diagnosis
market. Savicell deploys Well-Shield™ technology, a Liquid ImmunoBiopsy™
diagnostic platform. In contrast to existing technologies that evaluate secretions
of cancer cells, Well-Shield’s ImmunoBiopsy platform receives data directly
from the immune system. Importantly, Well-Shield is different in that it is
a functional test measuring the metabolic activation profile of the immune system
as an indicator of disease status. As an immune system test, it is inherently
suited for early detection.
The technology has now received intellectual property protection with a patent
approved in the United States, China, Japan and Europe. Furthermore, the patent
process is ongoing in several other countries.
Disease intrusion and cell malformation, including cancer, are first detected
by the immune system, which energizes to rid the body of the malignancy. The
initial immune response to disease is intricate, deploying different metabolic
pathways and subtypes of cells. The Well-ShieldTM technology is designed to
detect and interpret these differential metabolic responses.